Cardiol Therapeutics Inc(CRDL-T)
TSX

Today's Change
Real-Time Last Update
Day Low1.51
Day High1.51
Open:1.51
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Select a category then submit the form to load news
Baystreet
Stocks in play: Cardiol Therapeutics Inc.
Newswire.ca
Cardiol Therapeutics to Participate in Fireside Chat at H.C. Wainwright 4th Annual BioConnect Investor Conference at the NASDAQ
Baystreet
Stocks in play: Cardiol Therapeutics Inc.
Newswire.ca
Cardiol Therapeutics' Phase II MAvERIC Results Accepted for Publication in the Journal of the American Heart Association
Baystreet
Stocks in play: Cardiol Therapeutics Inc.
Newswire.ca
Cardiol Therapeutics Expands U.S. MAVERIC Phase III Trial Network to Address Growing Interest in the Pivotal Program
Newsfile
Upcoming Meeting Dates - April 20, 2026
Baystreet
Stocks in play: Cardiol Therapeutics Inc.
Newsfile
Cardiol Therapeutics to Highlight MAVERIC Phase III Trial and Recently Published ARCHER Results in Live Interview with Barchart
Newsfile
Cardiol Therapeutics Announces Year-End 2025 Update on Operations
Newsfile
Cardiol Therapeutics to Present at TD Cowen 46th Annual Health Care Conference
Baystreet
Stocks in play: Cardiol Therapeutics Inc.
Newsfile
Cardiol Therapeutics' ARCHER Phase II Study Results Published in ESC Heart Failure
Newsfile
Cardiol Therapeutics Announces Closing of Bought Deal Financing and Full Exercise of Over-Allotment Option for Gross Proceeds of $14.85 Million
Newsfile
Cardiol Therapeutics Inc. Announces Bought Deal Financing for Gross Proceeds of $13.5 Million
Newsfile
Cardiol Therapeutics Announces Bought Deal Financing for Gross Proceeds of $13.5 Million
Baystreet
Stocks in play: Cardiol Therapeutics Inc.
Newsfile
Cardiol Therapeutics Achieves Key 50% Patient Enrollment Milestone in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis
PressReach
New Data from the Phase II ARCHER Trial Demonstrate CardiolRx(TM) Improves Heart Structure in Patients with Acute Myocarditis, Supporting Expansion Across Inflammatory Cardiac Conditions

Profile

Cardiol Therapeutics Inc is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. Its primary small-molecule candidate, CardiolRx, targets inflammasome pathway activation, which is involved in the development of inflammation and fibrosis in conditions such as pericarditis, myocarditis, and heart failure. The CardiolRx program includes the completed Phase II MAVERIC-Pilot study and the ongoing Phase III MAVERIC trial for the treatment of pericarditis. The ARCHER program evaluated CardiolRx in acute myocarditis through a completed Phase II study. The company is also developing CRD-38, a novel subcutaneous drug formulation for treating inflammatory heart conditions, including heart failure.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.